Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 3, 2013, Pages 356-364

  Healey, Gareth D ^a   Evans, Neil ^a   Hopkin, Julian M ^a   Davies, Gwyneth ^a   Walker, William ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Asthma; Biomarker; CCL26; Nasal epithelium; Preclinical; SiRNA; STAT6

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; SMALL INTERFERING RNA; STAT6 PROTEIN; STAT6 PROTEIN, HUMAN;

ADULT; ARTICLE; ASTHMA; CASE CONTROL STUDY; COMPARATIVE STUDY; DNA MICROARRAY; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NOSE MUCOSA; PATHOLOGY; PILOT STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADULT; ASTHMA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT6 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84875796596     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12014     Document Type: Article

References (49)

1. Akimoto T, Numata F, Tamura M, et al. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med. 1998; 187: 1537-42.
2. Kuperman DA, Schleimer RP. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med. 2008; 8: 384-92.
3. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004; 202: 175-90.
4. Izuhara K, Arima K, Kanaji S, et al. IL-13: a promising therapeutic target for bronchial asthma. Curr Med Chem. 2006; 13: 2291-8.
5. Izuhara K, Shirakawa T, Adra CN, et al. Emerging therapeutic targets in allergy: IL-4Rα and Stat6. Emerging Therapeutic Targets. 1999; 3: 381-9.
6. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT6 pathway for the treatment of asthma. Eur Resp Rev. 2010; 115: 46-54.
7. Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nature Med. 2002; 8: 885-9.
8. Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol. 2007; 28: 248-51.
9. Kato A, Schleimer RP. Beyond inflammation: epithelial cells are at the interface of innate and adaptive immunity. Current Opinion Immunol. 2007; 19: 1-10.
10. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respirat Med. 2006; 100: 1297-306.
11. Frois C, Wu EQ, Ray S, et al. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther. 2009; 31: 2779-803.
12. Walker W, Healey GD, Hopkin JM. RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology. 2009; 127: 256-66.
13. Healey GD, Zinnen S, Lockridge JA, et al. Identification of small interfering RNA targeting signal transducer and activator of transcription 6: characterisation and selection of candidates for pre-clinical development. J RNAi Gene Silencing. 2010; 25: 401-10.
14. Finkelman FD, Wills-Karp M. Usefulness and optimization of mouse models of allergic airway disease. J Allergy Clin Immunol. 2008; 121: 603-6.
15. Wenzel S, Holgate ST. The mouse trap: it still yields few answers in asthma. Am J Respir Crit Care Med. 2006; 174: 1173-6.
16. Di Valentin E, Crahay C, Garbacki N, et al. New asthma biomarkers: lessons from murine models of acute and chronic asthma. Am J Physiol Lung Cell Mol Physiol. 2009; 296: L185-97.
17. Murugan A, Prys-Ricard C, Calhoun WJ. Biomarkers in asthma. Curr Opin Pulm Med. 2009; 15: 12-8.
18. Braunstahl G-J. United airways concept. What does it teach us about systemic inflammation in airways disease? Proc Am Thorac Soc. 2009; 6: 652-4.
19. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003; 111: 1171-83.
20. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines. 2010 revision. J Allergy Clin Immunol. 2010; 126: 466-76.
21. Dimova S, Brewster ME, Noppe M, et al. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol In Vitro. 2005; 19: 107-22.
22. Erin EM, Leaker BR, Zacharasiewicz A, et al. Effects of a reversible β-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin Exp Allergy. 2006; 36: 458-64.
23. Bai S, Yang T, Abbruscato TJ, et al. Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. J Pharma Sci. 2008; 97: 1165-78.
24. Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med. 2008; 358: 1682-91.
25. Ravensberg AJ, Ricciardolo FLM, van Schadewijk A, et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol. 2005; 115: 779-85.
26. Eurich K, Segawa M, Toei-Shimizu S, et al. Potential role of chitinase 3-like-1in inflammation-associated carcinogenic changes of epithelial cells. World J Gasrroenterol. 2009; 15: 5249-59.
27. van Wetering S, Zuyderduyn S, Ninaber DK, et al. Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. Mol Immunol. 2007; 44: 803-11.
28. Hartl D, Lee CG, Da Silva CA, et al. Novel biomarkers in asthma: chemokines and chitinase-like proteins. Curr Opin Allergy Clin Immunol. 2009; 9: 60-6.
29. Ross AJ, Dailey LA, Brighton LE, et al. Transcriptional profiling of mucociliary differentiation in human airway epithelial cells. Am J Respir Cell Mol Biol. 2007; 37: 169-85.
30. GINA. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Available from: http://www.ginasthma.org/.
31. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987; 136: 225-44.
32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: 2002-7.
33. Bitterle E, Karg E, Schroeppel A, et al. Dose-controlled exposure of A549 epithelial cells at the air-liquid interface to airborne ultrafine carbonaceous particles. Chemosphere. 2006; 65: 1784-90.
34. Lin H, Li H, Cho H-J, et al. Air-liquid interface (ALI) cultures of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharma Sci. 2007; 96: 341-50.
35. Erin EM, Zacharasiewicz AS, Nicholoson GC, et al. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin Exp Allergy. 2005; 35: 1608-14.
36. Howarth PH, Persson CG, Meltzer EO, et al. Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol. 2005; 115: s414-41.
37. Bourdin A, Gras D, Vachier I, et al. Upper airway. 1. Allergic rhinitis and asthma: united disease through epithelial cells. Thorax. 2009; 64: 999-1004.
38. Syed F, Huang CC, Li K, et al. Identification of interleukin-13 related biomarkers using peripheral blood mononuclear cells. Biomarkers. 2007; 12: 414-23.
39. Kraft M. Asthma phenotypes and interleukin-13-moving closer to personalized medicine. N Engl J Med. 2011; 365: 1141-4.
40. Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol. 2001; 24: 755-61.
41. Chhin B, Pham JT, El Zein L, et al. Identification of transcripts overexpressed during airway epithelium differentiation. Eur Respir J. 2008; 32: 121-8.
42. Chu Q, Tousignant JD, Fang S, et al. Binding and uptake of cationic lipid: pDNA complexes by polarized airway epithelial cells. Human Gene Ther. 1999; 10: 25-36.
43. Mennesson E, Erbacher P, Piller V, et al. Transfection efficiency and uptake process of polyplexes in human lung endothelial cells: a comparative study in non-polarized and polarized cells. J Gene Med. 2005; 7: 729-38.
44. Heijink IH, van Oosterhout A, Kapus A. Epidermal growth factor receptor signalling contributes to house dust mite-induced epithelial barrier dysfunction. Eur Respir J. 2010; 36: 1016-26.
45. Lachowicz-Scroggins ME, Boushey HA, Finkbeiner WE, et al. Interleukin-13-induced mucous metaplasia increases susceptibility of human airway epithelium to rhinovirus infection. Am J Respir Cell Mol Biol. 2010; 43: 652-61.
46. Christodoulopoulos P, Cameron L, Nakamura Y, et al. Th2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. J Allergy Clin Immunol. 2001; 107: 586-91.
47. Ghaffar O, Christodoulopoulos P, Lamkhioued B, et al. In vivo expression of signal transducer and activator of transcription factor 6 (STAT6) in nasal mucosa from atopic allergic rhinitis: effect of topical corticosteroids. Clin Exp Allergy. 2000; 30: 86-93.
48. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy. 2003; 58: 691-706.
49. McDougall CM, Blaylock MG, Douglas JG, et al. Nasal epithelial cells as surrogates for bronchial epithelial cells in airway inflammation studies. Am J Respir Cell Mol Biol. 2008; 39: 560-8.